Barrington Research reissued their outperform rating on shares of HealthEquity (NASDAQ:HQY – Free Report) in a report published on Friday, Benzinga reports. They currently have a $105.00 target price on the stock.
HQY has been the subject of several other research reports. Royal Bank of Canada reaffirmed an outperform rating and issued a $92.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. Raymond James boosted their price target on HealthEquity from $100.00 to $105.00 and gave the stock an outperform rating in a research note on Friday, June 7th. Wells Fargo & Company boosted their price target on HealthEquity from $107.00 to $110.00 and gave the stock an overweight rating in a research note on Thursday, June 20th. JMP Securities reiterated a market outperform rating and issued a $105.00 price target on shares of HealthEquity in a research note on Wednesday, September 4th. Finally, KeyCorp boosted their price target on HealthEquity from $95.00 to $100.00 and gave the stock an overweight rating in a research note on Wednesday, June 5th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average target price of $103.83.
Read Our Latest Report on HealthEquity
HealthEquity Price Performance
Insider Buying and Selling at HealthEquity
In other HealthEquity news, Director Frank Corvino sold 7,705 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $81.89, for a total transaction of $630,962.45. Following the sale, the director now owns 6,070 shares in the company, valued at $497,072.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Frank Corvino sold 7,705 shares of the stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $81.89, for a total transaction of $630,962.45. Following the sale, the director now directly owns 6,070 shares in the company, valued at approximately $497,072.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total value of $2,795,100.00. Following the sale, the insider now owns 89,769 shares in the company, valued at $7,168,952.34. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by insiders.
Institutional Trading of HealthEquity
A number of institutional investors and hedge funds have recently made changes to their positions in HQY. Rise Advisors LLC bought a new position in HealthEquity in the 1st quarter worth approximately $28,000. Cape Investment Advisory Inc. bought a new position in HealthEquity in the 4th quarter worth approximately $27,000. International Assets Investment Management LLC bought a new position in HealthEquity in the 2nd quarter worth approximately $35,000. YHB Investment Advisors Inc. bought a new position in HealthEquity in the 1st quarter worth approximately $40,000. Finally, Fidelis Capital Partners LLC bought a new position in HealthEquity in the 1st quarter worth approximately $42,000. 99.55% of the stock is currently owned by institutional investors and hedge funds.
About HealthEquity
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Recommended Stories
- Five stocks we like better than HealthEquity
- What is Short Interest? How to Use It
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- Stock Market Sectors: What Are They and How Many Are There?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- The 3 Best Blue-Chip Stocks to Buy Now
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.